|Articles|October 8, 2007
Cleveland Clinic's Cole Eye Institute receives $310,000 grant
Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.
Advertisement
Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.
One of the main focuses of the research is to treat diabetic retinopathy.
According to the American Academy of Ophthalmology, the disease is the leading cause of blindness among working Americans.
The study will evaluate whether a cellular therapy product by Arteriocyte could prevent the initial vaso-degenerative phase of the disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
3
EURETINA 2026: Real-world evidence on retinal biosimilars
4
EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts
5











